U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Amyotrophic lateral sclerosis type 8(ALS8)

MedGen UID:
325237
Concept ID:
C1837728
Disease or Syndrome
Synonyms: ALS8; VAPB-Related Amyotrophic Lateral Sclerosis
SNOMED CT: ALS8 - amyotrophic lateral sclerosis type 8 (1204350002); Amyotrophic lateral sclerosis type 8 (1204350002)
 
Gene (location): VAPB (20q13.32)
 
Monarch Initiative: MONDO:0012077
OMIM®: 608627

Definition

A neurodegenerative disease with characteristics of progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. Caused by heterozygous mutation in the VAPB gene on chromosome 20q13. [from SNOMEDCT_US]

Clinical features

From HPO
Dysphagia
MedGen UID:
41440
Concept ID:
C0011168
Disease or Syndrome
Difficulty in swallowing.
Amyotrophic lateral sclerosis
MedGen UID:
274
Concept ID:
C0002736
Disease or Syndrome
Amyotrophic lateral sclerosis (ALS) is a progressive disease that affects motor neurons, which are specialized nerve cells that control muscle movement. These nerve cells are found in the spinal cord and the brain. In ALS, motor neurons die (atrophy) over time, leading to muscle weakness, a loss of muscle mass, and an inability to control movement.\n\nThere are many different types of ALS; these types are distinguished by their signs and symptoms and their genetic cause or lack of clear genetic association. Most people with ALS have a form of the condition that is described as sporadic, which means it occurs in people with no apparent history of the disorder in their family. People with sporadic ALS usually first develop features of the condition in their late fifties or early sixties. A small proportion of people with ALS, estimated at 5 to 10 percent, have a family history of ALS or a related condition called frontotemporal dementia (FTD), which is a progressive brain disorder that affects personality, behavior, and language. The signs and symptoms of familial ALS typically first appear in one's late forties or early fifties. Rarely, people with familial ALS develop symptoms in childhood or their teenage years. These individuals have a rare form of the disorder known as juvenile ALS.\n\nThe first signs and symptoms of ALS may be so subtle that they are overlooked. The earliest symptoms include muscle twitching, cramping, stiffness, or weakness. Affected individuals may develop slurred speech (dysarthria) and, later, difficulty chewing or swallowing (dysphagia). Many people with ALS experience malnutrition because of reduced food intake due to dysphagia and an increase in their body's energy demands (metabolism) due to prolonged illness. Muscles become weaker as the disease progresses, and arms and legs begin to look thinner as muscle tissue atrophies. Individuals with ALS eventually lose muscle strength and the ability to walk. Affected individuals eventually become wheelchair-dependent and increasingly require help with personal care and other activities of daily living. Over time, muscle weakness causes affected individuals to lose the use of their hands and arms. Breathing becomes difficult because the muscles of the respiratory system weaken. Most people with ALS die from respiratory failure within 2 to 10 years after the signs and symptoms of ALS first appear; however, disease progression varies widely among affected individuals.\n\nApproximately 20 percent of individuals with ALS also develop FTD. Changes in personality and behavior may make it difficult for affected individuals to interact with others in a socially appropriate manner. Communication skills worsen as the disease progresses. It is unclear how the development of ALS and FTD are related. Individuals who develop both conditions are diagnosed as having ALS-FTD.\n\nA rare form of ALS that often runs in families is known as ALS-parkinsonism-dementia complex (ALS-PDC). This disorder is characterized by the signs and symptoms of ALS, in addition to a pattern of movement abnormalities known as parkinsonism, and a progressive loss of intellectual function (dementia). Signs of parkinsonism include unusually slow movements (bradykinesia), stiffness, and tremors. Affected members of the same family can have different combinations of signs and symptoms.
Dysarthria
MedGen UID:
8510
Concept ID:
C0013362
Mental or Behavioral Dysfunction
Dysarthric speech is a general description referring to a neurological speech disorder characterized by poor articulation. Depending on the involved neurological structures, dysarthria may be further classified as spastic, flaccid, ataxic, hyperkinetic and hypokinetic, or mixed.
Fasciculations
MedGen UID:
5124
Concept ID:
C0015644
Sign or Symptom
Fasciculations are observed as small, local, involuntary muscle contractions (twitching) visible under the skin. Fasciculations result from increased irritability of an axon (which in turn is often a manifestation of disease of a motor neuron). This leads to sporadic discharges of all the muscle fibers controlled by the axon in isolation from other motor units.
Abnormal pyramidal sign
MedGen UID:
68582
Concept ID:
C0234132
Sign or Symptom
Functional neurological abnormalities related to dysfunction of the pyramidal tract.
Areflexia
MedGen UID:
115943
Concept ID:
C0234146
Finding
Absence of neurologic reflexes such as the knee-jerk reaction.
Postural tremor
MedGen UID:
66696
Concept ID:
C0234378
Sign or Symptom
A type of tremors that is triggered by holding a limb in a fixed position.
Cognitive impairment
MedGen UID:
90932
Concept ID:
C0338656
Mental or Behavioral Dysfunction
Abnormal cognition is characterized by deficits in thinking, reasoning, or remembering.
Loss of ambulation
MedGen UID:
332305
Concept ID:
C1836843
Finding
Inability to walk in a person who previous had the ability to walk.
Neuronal loss in central nervous system
MedGen UID:
342515
Concept ID:
C1850496
Finding
Bulbar signs
MedGen UID:
347246
Concept ID:
C1856507
Finding
Abnormal pyramidal tract morphology
MedGen UID:
892809
Concept ID:
C4021761
Anatomical Abnormality
Any structural abnormality of the pyramidal tract, whose chief element, the corticospinal tract, is the only direct connection between the brain and the spinal cord. In addition to the corticospinal tract, the pyramidal system includes the corticobulbar, corticomesencephalic, and corticopontine tracts.
Muscle spasm
MedGen UID:
52431
Concept ID:
C0037763
Sign or Symptom
Sudden and involuntary contractions of one or more muscles.
Proximal muscle weakness
MedGen UID:
113169
Concept ID:
C0221629
Finding
A lack of strength of the proximal muscles.
Progressive muscle weakness
MedGen UID:
68704
Concept ID:
C0240421
Finding
Distal muscle weakness
MedGen UID:
140883
Concept ID:
C0427065
Finding
Reduced strength of the musculature of the distal extremities.
Muscular atrophy
MedGen UID:
892680
Concept ID:
C0541794
Pathologic Function
The presence of skeletal muscular atrophy (which is also known as amyotrophy).
Distal amyotrophy
MedGen UID:
338530
Concept ID:
C1848736
Disease or Syndrome
Muscular atrophy affecting muscles in the distal portions of the extremities.
Proximal amyotrophy
MedGen UID:
342591
Concept ID:
C1850794
Disease or Syndrome
Amyotrophy (muscular atrophy) affecting the proximal musculature.

Professional guidelines

PubMed

James E, Ellis C, Brassington R, Sathasivam S, Young CA
Cochrane Database Syst Rev 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. PMID: 35593746Free PMC Article
Holecek V, Rokyta R
Neuro Endocrinol Lett 2018 Feb;38(8):528-531. PMID: 29504729
Hübers A, Hildebrandt V, Petri S, Kollewe K, Hermann A, Storch A, Hanisch F, Zierz S, Rosenbohm A, Ludolph AC, Dorst J
J Neurol 2016 Feb;263(2):390-395. Epub 2015 Dec 24 doi: 10.1007/s00415-015-7993-z. PMID: 26705123

Curated

Orphanet, Amyotrophic lateral sclerosis, 2007

Recent clinical studies

Etiology

Gomes NA, das Chagas Lima E Silva F, de Oliveira Volpe CM, Villar-Delfino PH, de Sousa CF, Rocha-Silva F, Nogueira-Machado JA
Curr Neuropharmacol 2023;21(3):482-490. doi: 10.2174/1570159X21666230201151016. PMID: 36722478Free PMC Article

Diagnosis

Stump AL, Rioux DJ, Albright R, Melki GL, Prosser DC
Biomolecules 2023 Jul 19;13(7) doi: 10.3390/biom13071147. PMID: 37509182Free PMC Article
de Alcântara C, Cruzeiro MM, França MC Jr, Camargos ST, de Souza LC
J Neurol 2019 Aug;266(8):1980-1987. Epub 2019 May 14 doi: 10.1007/s00415-019-09369-y. PMID: 31089860
Gkogkas C, Wardrope C, Hannah M, Skehel P
J Neurochem 2011 Apr;117(2):286-94. Epub 2011 Feb 24 doi: 10.1111/j.1471-4159.2011.07201.x. PMID: 21275991

Prognosis

Oliveira D, Morales-Vicente DA, Amaral MS, Luz L, Sertié AL, Leite FS, Navarro C, Kaid C, Esposito J, Goulart E, Caires L, Alves LM, Melo US, Figueiredo T, Mitne-Neto M, Okamoto OK, Verjovski-Almeida S, Zatz M
Hum Mol Genet 2020 Jun 3;29(9):1465-1475. doi: 10.1093/hmg/ddaa069. PMID: 32280986

Clinical prediction guides

Gomes NA, das Chagas Lima E Silva F, de Oliveira Volpe CM, Villar-Delfino PH, de Sousa CF, Rocha-Silva F, Nogueira-Machado JA
Curr Neuropharmacol 2023;21(3):482-490. doi: 10.2174/1570159X21666230201151016. PMID: 36722478Free PMC Article
de Alcântara C, Cruzeiro MM, França MC Jr, Camargos ST, de Souza LC
J Neurol 2019 Aug;266(8):1980-1987. Epub 2019 May 14 doi: 10.1007/s00415-019-09369-y. PMID: 31089860

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...